M
USCLE wasting is a hallmark of many pathophysiological conditions, including viral and bacterial infections (1), cancer (2) , chronic alcohol abuse (3) , and the acquired immune deficiency syndrome (AIDS) (4) . The erosion of lean body mass significantly contributes to both the morbidity and mortality associated with catabolic diseases (5) . Although the mechanism by which patients lose muscle mass remains to be completely defined, both a decrease in muscle protein synthesis and an increase in muscle protein degradation are likely to be involved (2, 3, 6 -8) .
Muscle mass and nitrogen balance are influenced by hormones functioning in an endocrine fashion (1, 9) , as well as by the autocrine production of proinflammatory cytokines (4, 10) . Insulin-like growth factor I (IGF-I) is a hormone that stimulates muscle protein synthesis (11, 12) and impairs protein degradation (12) . The plasma concentration of IGF-I is reduced in sepsis (1, 9, 13) , in critically ill patients (14) , in individuals with AIDS (15) , and in other catabolic conditions (16) . It is postulated that muscle wasting results from both a decrease in the intramuscular concentration of IGF-I (17) and changes in the responsiveness of muscle to stimulation by IGF-I (8, 18, 19) .
The plasma concentration of the proinflammatory cytokine tumor necrosis factor-␣ (TNF-␣) is elevated in sepsis (20, 21) , neoplastic disease (2, 10) , and in AIDS (4, 22) . During some catabolic states, the increase in TNF-␣ appears sustained, whereas in other conditions, the elevation is relatively transient (i.e. several hours). Furthermore, the administration of TNF-␣ to normal animals induces cachexia and rapidly alters the serum concentration of IGF-I and IGF binding proteins (23) . Yet, the ability of TNF-␣ and other cytokines to directly influence muscle protein metabolism remains controversial. TNF-␣ has been shown to have either no effect on muscle protein metabolism (24, 25) or to decrease muscle protein synthesis (26, 27) . Indeed a single laboratory has shown TNF-␣ to have distinct effects under different experimental conditions (25) (26) (27) . In addition, the interpretation of data from in vivo studies is confounded by the ability of TNF-␣ to stimulate the production of a cascade of other cytokines (21) . Thus, it is difficult to conclude whether TNF-␣ has a direct effect on protein synthesis or whether the observed changes are secondary to perturbations in other hormones.
Because IGF-I positively influences both whole body and muscle protein synthesis (12), we have examined whether IGF-I can stimulate protein synthesis in human myoblasts and whether its biological activity can be influenced by TNF-␣. In addition, because TNF-␣ expression is often only transient but its effects long lasting, we examined whether protein synthesis in human myoblasts is altered by a brief exposure to TNF-␣.
Methods

Cell culture
Normal human myoblasts were purchased from Clonetics Corp. (San Diego, CA) and cultured in skeletal muscle growth media containing epidermal growth factor, insulin, BSA, fetuin, and dexamethasone (Clonetics). Cells were subsequently grown in MEM (Mediatech, Herndon, VA) supplemented with 5% newborn calf serum (Sigma, St. Louis, MO), penicillin (0.1 U/liter), streptomycin (0.1 g/liter), and amphotericin B (0.25 ng/liter). Cells were subcultured into 24-well cluster dishes (Falcon, Lincoln Park, NJ) and grown in serum-free media for 72 h for subsequent measurement of DNA and protein synthesis. In some experiments, cells were switched to MEM containing 2% horse serum (Sigma) and 4 m cytosine arabinoside for 3 days to obtain fused myotubes, as described by Blau and Webster (28) .
[ 3 
H]Thymidine uptake
Human myoblasts in 24-well dishes (1.5 ϫ 10 5 cells/well) were treated with either serum-free MEM alone, recombinant human IGF-I (Upstate Biotechnology, Lake Placid, NY), recombinant human TNF-␣ (PeproTech, Princeton, NJ), or a combination of both peptides for 21 h. Cells were labeled with [
3 H]methylthymidine (6.7 Ci/mmol, Dupont-NEN, Boston, MA) at 0.5 Ci/well for the final 6 h. Cells were washed three times in ice-cold HBSS, isolated in trypsin-EDTA, and precipitated at 4 C overnight with 5% trichloroacetic acetic acid (TCA), as previously described (29) . After washing, TCA precipitable radioactivity was solubilized in 1 n sodium hydroxide and liquid scintillation cocktail (Scintverse II; Fisher Scientific, Springfield, NJ) and counted in a liquid scintillation counter (Wallac, Gaithersburg, MD).
Protein synthesis
Human myoblasts were treated as described above with either MEM alone, IGF-I, TNF-␣, or a combination of both peptides for 5 h. Cells were labeled with 2 Ci/well of [ 3 H]phenylalanine (132 Ci/mmol, Amersham, Arlington Heights, IL) for the entire period. Cells were washed and isolated as described above and precipitated overnight at 4 C with 10% TCA. In some experiments, the TCA precipitate was base hydrolyzed in 0.3 n sodium hydroxide for 0.5 h at 37 C to solubilize nucleic acid-bound phenylalanine. Radioactively labeled protein was subsequently reprecipitated with TCA. Human serum used in these experiments was collected from adult male volunteers after an overnight fast (30) . Serum was pooled and diluted into culture media to a final concentration of 0.25%. Similar results were observed when the serum pool was obtained from the same individuals 4 h after being fed.
IGF-I binding assays
Human recombinant IGF-I was iodinated with [
125 I]radionuclide (Amersham) and purified by gel filtration chromatography, as previously described (31) . Human myoblasts were grown and subcultured into 24-well cluster plates as described above. Forty minutes before the binding assays, half of the wells were incubated with TNF-␣ (100 ng/ ml). Cells were subsequently rinsed with ice-cold HBSS and incubated with 125 I-labeled IGF-I in HBSS with 0.1% gelatin at 4 C for 12 h in the presence of increasing amounts of unlabeled IGF-I. Cells were rinsed with HBSS, solubilized in 1 n sodium hydroxide, and bound radioactivity measured in a ␥-counter (Wallac). Results are expressed as the percentage of 125 I-labeled IGF-I bound to myoblasts after subtraction of nonspecific binding determined in the presence of 1 g/ml unlabeled IGF-I.
Statistical analysis
All experiments were repeated on at least three separate occasions. Individual data points are expressed as the mean Ϯ se for triplicate wells. Statistical comparisons were made by ANOVA followed by StudentNewman-Keuls test to determine treatment effect. Statistical significance was set at P Ͻ 0.05.
Results
Serum and IGF-I stimulate protein synthesis in human myoblasts
IGF-I has previously been shown to stimulate amino acid uptake (32) and protein synthesis (33) in the rat L6 muscle cell line. In this study, we examined whether a similar stimulation occurs in human myoblasts. Protein synthesis was measured by labeling cells with [ 3 H]phenylalanine. Protein synthesis was linear with the amount of tracer added to the cells (r ϭ 0.998), incubation time (r ϭ 0.997), and the number of cells/well (r ϭ 0.993) (data not shown). Human serum stimulated protein synthesis in myoblasts dose dependently (Fig.  1A) . Maximal stimulation occurred with as little as 0.25% human serum. IGF-I also stimulated protein synthesis dosedependently (Fig. 1B) . Half-maximal stimulation occurred at 8 ng/ml. The response of myoblasts to IGF-I was not altered by increasing concentrations of unlabeled phenylalanine (0.2-0.8 mm). In addition, the incorporation of
A, Human myoblasts were cultured in presence of a pool of human serum at a final concentration between 0 -0.5% for 5 h. TCAprecipitable radioactivity from isolated cells was determined in a liquid scintillation counter after washing as outlined in Methods. B, Human myoblasts were cultured in presence of IGF-I at a final concentration between 0 -50 ng/ml, and protein synthesis was determined as described above. Values are mean Ϯ SE (n ϭ 3). For this and all subsequent figures, where absent, SE bars are within symbol.
alanine into protein was confirmed by the ability of the protein synthesis inhibitor cycloheximide to inhibit incorporation ( Fig. 2A ) and by the resistance of TCA precipitable material to base hydrolysis (Fig. 2B) . Similar results were also obtained when [ 3 H]tyrosine was used as the labeled amino acid (data not shown). These data demonstrate that protein synthesis can be quantitated in human myoblasts, and that myoblasts are responsive to both human serum and IGF-I.
TNF-␣ inhibits IGF-I-stimulated protein synthesis
TNF-␣ is elevated in pathophysiological conditions characterized by muscle wasting. Therefore, we examined whether TNF-␣ could inhibit basal and/or IGF-I stimulated protein synthesis in human myoblasts. TNF-␣ (100 ng/ml) decreased basal protein synthesis in human myoblasts by 15% (Fig. 3A) . IGF-I (40 ng/ml) stimulated protein synthesis by 18%. The effect of this maximally stimulating dose of IGF-I was completely inhibited by the addition of TNF-␣ (100 ng/ml) to the cells (P Ͻ 0.05). TNF-␣ inhibited the ability of IGF-I to stimulate protein synthesis in a dose-dependent manner (Fig. 3B) . Statistically significant inhibition of this response occurred with as little as 2 ng/ml of TNF-␣.
TNF-␣ inhibits protein synthesis irrespective of sequence of addition of growth factors
Because IGF-I is only one of several serum growth factors responsible for stimulating protein and DNA synthesis, we examined whether TNF-␣ could also inhibit the ability of whole serum to stimulate protein synthesis. TNF-␣ inhibited protein synthesis when it was added simultaneously with serum, or if it was added 30 min after myoblasts had been exposed to serum (Fig. 4A) . TNF-␣ also inhibited protein synthesis when it was added 30 min before the addition of serum and then removed for the remainder of the experiment (Fig. 4A) . Similar results were obtained when IGF-I was added to the cells instead of serum (Fig. 4B) .
Transient exposure to TNF-␣ inhibits serum-stimulated protein synthesis
We examined whether short-term exposure of human myoblasts to TNF-␣ could inhibit the ability of serum to subsequently stimulate protein synthesis, because the host is often only transiently exposed to elevated plasma concen- trations of cytokines. Exposure of human myoblasts to TNF-␣ for as little as 10 min inhibited the ability of serum to stimulate protein synthesis over the next 6 h (Fig. 5A) . Exposure of cells to TNF-␣ for 20 min also inhibited the ability of serum to stimulate protein synthesis when cells were challenged with serum 48 h later (Fig. 5B) .
TNF-␣ does not inhibit IGF-I-or serum-stimulated thymidine uptake
Because TNF-␣ has been shown to inhibit insulin-stimulated glucose uptake in L6 myoblasts (34), we questioned whether TNF-␣ inhibited serum-stimulated events in general or whether it selectively inhibited protein synthesis. Therefore, we examined whether TNF-␣ inhibited the ability of serum and IGF-I to stimulate thymidine uptake in human myoblasts. IGF-I (40 ng/ml) and serum (0.25%) stimulated thymidine uptake by 70% and 80%, respectively (Fig. 6, A  and B) . Although TNF-␣ completely inhibited the ability of serum and IGF-I to stimulate protein synthesis, it failed to inhibit growth factor-stimulated thymidine uptake (Fig. 6, A  and B ). There was a trend toward TNF-␣ inhibiting basal thymidine uptake in the absence of growth factors, but this response did not reach statistical significance. Moreover, the affect of TNF-␣ was overcome by either serum or IGF-I (Fig.  6, A and B) . These data show that serum and IGF-I are biologically active in the presence of TNF-␣, and that TNF-␣ selectively inhibits only a portion of growth factor stimulated events in human myoblasts.
TNF-␣ does not alter IGF-I binding to myoblasts
Because TNF-␣ may inhibit protein synthesis by altering IGF receptor binding characteristics on myoblasts, we examined whether TNF-␣ affected the ability of 125 I-labeled IGF-I to bind to human myoblasts. Pretreatment of myoblasts with TNF-␣ (100 ng/ml) for 40 min had no affect on either the maximal binding of IGF-I to myoblasts or the affinity of the IGF-I receptor for IGF-I (Fig. 7) .
FIG. 4. TNF-␣ and either 0.25% serum (A) or IGF-I (B)
were added to human myoblasts at different times to examine whether sequence in which cells are exposed to these factors is critical for stimulation or inhibition of protein synthesis. Absence of a factor is denoted by a negative sign. Presence of a factor is denoted by time in minutes at which factor was added. Cells exposed to TNF-␣ (100 ng/ml) and IGF-I (40 ng/ml) simultaneously at beginning of experiment are denoted 0 ϩ 0. Origin for ordinate has been set at 3000 dpm/well to make differences between experimental conditions more apparent. Values are mean Ϯ SE (n ϭ 3); *, P Ͻ 0.01 compared with control; †, P Ͻ 0.05 compared with either IGF-I or 0.25% serum alone.
FIG. 5.
A, Human myoblasts were exposed to either serum alone or TNF-␣ (100 ng/ml) for 10 min or 20 min followed by washing and an immediate challenge with serum. Protein synthesis was measured as described in Fig. 1 over following 5 h. B, Human myoblasts were exposed to either serum-free MEM or TNF-␣ (100 ng/ml) for 20 min followed by washing and growth in serum-free media. Cells were subsequently challenged with 0.25% serum 48 h later and protein synthesis measured as described above. Origin for ordinate has been set at 6000 dpm/well to make differences between experimental conditions more apparent. Values are mean Ϯ SE (n ϭ 6); * P Ͻ 0.001 compared with control; †, P Ͻ 0.001 compared with 0.25% serum alone.
TNF-␣ inhibits serum-stimulated protein synthesis in myotubes
Because there is some concern whether observations made in human myoblasts can be extrapolated to responses in differentiated muscle, we treated myoblasts with horse serum and cytosine arabinoside to obtain fused myotubes as described by Blau and Webster (28) . Human myotubes responded to serum with a 22% increase in protein synthesis (Fig. 8) . TNF-␣ completely inhibited the ability of serum to stimulate protein synthesis in myotubes (Fig. 8) . These responses are similar to those that we have observed for myoblasts.
Discussion
Our data demonstrate that protein synthesis can be studied in human myoblasts and myotubes. We have found human myoblasts to be responsive to human serum, growth factors, and TNF-␣. The current data are consistent with previous work by Ewton et al. (32) and Ballard et al. (33) showing that IGF-I stimulates amino acid uptake and protein synthesis in the rat L6 muscle cell line. Our work is also consistent with the finding by Fryburg (12) , that IGF-I stimulates protein synthesis in the forearm of healthy volunteers.
We demonstrate for the first time that TNF-␣ can directly inhibit both the basal level of protein synthesis, as well as the ability of serum and IGF-I to stimulate protein synthesis in myoblasts. TNF-␣ expression may occur transiently in response to infectious-like insults, but alterations in muscle protein balance are often manifested over relatively longer periods of time. Many of the in vivo effects of TNF-␣ have previously been attributed to its ability to stimulate the production of other cytokines (21) . However, our in vitro data shows that TNF-␣ can also directly inhibit protein synthesis. Exposure of myoblasts to TNF-␣ for as little as 10 min completely blocked the ability of serum and IGF-I to stimulate FIG. 6 . Effect of TNF-␣ on IGF-I-and serum-stimulated DNA synthesis. The ability of TNF-␣ to inhibit DNA synthesis in human myoblasts was examined after cells were stimulated with either IGF-I (40 ng/ml) (A) or 0.25% human serum (B). TNF-␣ slightly lowered basal level of DNA synthesis, but this change did not achieve statistical significance. Both IGF-I and serum stimulated DNA synthesis, and this increase was not inhibited by TNF-␣ (100 ng/ml). Values are mean Ϯ SE (n ϭ 3); *, P Ͻ 0.01 compared with control values. 8 . Effect of TNF-␣ on serum-stimulated protein synthesis in human myotubes. Human myoblasts were grown in 24-well cluster dishes and switched to MEM containing 2% horse serum and cytosine arabinoside. After 3 days, fused myotubes were grown in serum-free medium for 48 h, and protein synthesis determined as described in Fig. 1 . Values are mean Ϯ SE (n ϭ 3).
protein synthesis. Moreover, the ability of IGF-I to stimulate protein synthesis was impaired for at least 48 h after transient exposure to the cytokine. These data suggest that a transient increase in the plasma concentration of TNF-␣ may impair protein synthesis long after the cytokine has disappeared from the circulation.
The decrease in protein synthesis we observed in myoblasts and myotubes treated with TNF-␣ is similar to the inhibition of protein synthesis observed in skeletal muscle from septic animals (11) . In contrast to our results obtained in cell culture, perfusion of the hindlimb with IGF-I restores protein synthesis in the gastrocnemius of septic rats (11) . It is possible that the decrease in muscle protein synthesis observed in this model results not from a direct effect of cytokines on muscle, but from the dramatic decrease in the plasma concentration of IGF-I that occurs with the insult (13) . Perfusion of muscle with IGF-I may restore protein synthesis by simply reexposing muscle to a high concentration of IGF-I. It is also possible that the intramuscular concentration of TNF-␣ achieved in the animal model of sepsis (13) may be below the concentration used in the present study. Alternatively, myoblasts and myotubes may respond differently to IGF-I and TNF-␣ than does the hindlimb, which also contains nerve, adipose, and connective tissue.
The concentration of serum chosen for this study was based on reports that have shown DNA synthesis to be maximally stimulated at very low concentrations of serum (i.e. Ͻ 1%) (35) . Human serum, in the concentration range we have used, also contains the same amount of IGF-I that is necessary to maximally stimulate protein synthesis. This concentration of IGF-I is also comparable with that found in extracellular fluid to which muscle would be exposed, and the concentration of IGF-I that can be measured in rat muscle (17) . High concentrations of IGF-I gave a suboptimal response in human myoblasts. This response may result from a down-regulation of the IGF-I receptor at high concentrations of IGF-I (36).
TNF-␣ inhibited both IGF-I-stimulated protein synthesis and serum-stimulated protein synthesis in myoblasts. This suggests that TNF-␣ may have a dominant negative effect not only on the ability of IGF-I to stimulate protein synthesis, but also a negative effect on the ability of other anabolic factors that are present in serum. We have previously reported that TNF-␣ decreases both the plasma and intramuscular concentrations of IGF-I, and that there is a positive correlation between the decreased content of IGF-I and the impaired rate of protein synthesis in muscle of septic animals (17) . Thus, inflammatory stimuli appear to alter both the magnitude of the IGF-I signal, and the ability of the IGF-I signal to be efficiently transduced at the cellular level. These changes may, in part, be responsible for the reduction in muscle protein synthesis during infection and other conditions associated with the overexpression of TNF-␣.
We have found the effect of TNF-␣ on protein synthesis to persist well past the initial exposure of myoblasts to the cytokine. Our data suggest that TNF-␣ rapidly binds to myoblasts, and initiates a series of events that inhibit the ability of serum and IGF-I to stimulate protein synthesis. These cellular changes do not require continuous stimulation by TNF-␣, and suggest that a key component of the IGF-I signal transduction pathway is altered by exposure to TNF.
Exposure of human myoblasts to TNF-␣ did not alter IGF-I receptor binding characteristics. Therefore, it appears that TNF-␣ interferes with the IGF-I signal transduction pathway at a point distal to receptor binding and autophosphorylation. Our data suggest that the IGF-I signaling pathway bifurcates, and that TNF-␣ acts selectively on a component of the pathway that is necessary for stimulation of protein synthesis but not thymidine uptake. One possibility is that TNF-␣ interferes with kinases that are responsible for stimulating components of the protein synthetic machinery. IGF-I and insulin have been shown to stimulate the kinase that is responsible for phosphorylating ribosomal protein S6 (p70/S6 kinase) (37) . The p70/S6 kinase phosphorylates the eukaryotic initiation factor 4E (eIF4E) binding protein, PHAS-1, and thus stimulates protein synthesis (38) . p70/S6 kinase activity is also correlated with the translation of messenger RNAs for elongation factors and ribosomal proteins (39) . It is possible that TNF-␣ may inhibit this process and/or other components of the IGF-I signal transduction pathway that normally result in enhanced protein synthesis.
TNF-␣ did not significantly impair the stimulation of thymidine uptake by either serum or IGF-I. This suggests that the proteins necessary for thymidine uptake are present in the cell before addition of TNF-␣, or that TNF-␣ affects only the synthesis of a subset of proteins that are not required for thymidine uptake. TNF-␣ inhibited basal protein synthesis by only 20%, leaving up to 80% of the maximum protein synthetic capacity of the myoblast intact. This moderate change in protein synthesis may explain why DNA synthesis is able to proceed in cells treated with both TNF-␣ and IGF-I. The changes in DNA and protein synthesis we have observed are strikingly similar to the effect that the p70/S6 kinase inhibitor rapamycin has on cycling cells (40) .
TNF-␣ is cytostatic in many tumor cells, but is also a mitogen for fibroblasts (41, 42) . We find that there is a trend toward TNF-␣ inhibiting thymidine uptake in myoblasts, but that this effect does not reach statistical significance. This slight inhibition can be overcome with either serum or IGF-I. This confirms both the viability of the myoblasts and the selectivity of TNF action.
In conclusion, the results of the present study indicate that TNF-␣ directly inhibits both the basal level of protein synthesis and growth factor-stimulated protein synthesis in human myoblasts. TNF-␣ also inhibits the ability of serum to stimulate protein synthesis in myotubes. TNF-␣ acts rapidly, such that even a transient exposure to TNF-␣ is inhibitory. TNF-␣ does not inhibit IGF-I or serum-stimulated thymidine uptake, suggesting that TNF-␣ acts specifically on a component of the IGF-I signal transduction pathway involved in stimulating protein synthesis. Furthermore, transient exposure of myoblasts to TNF-␣ inhibits protein synthesis for 48 h without the need for other cytokines. Hence, the human myoblast culture system can be used to identify factors that affect muscle protein synthesis. This system will be useful in determining the mechanism(s) responsible for muscle wasting in various pathophysiological conditions.
